Literature DB >> 21607794

Mosapride citrate improves postoperative ileus of patients with colectomy.

Yoshitaka Toyomasu1, Erito Mochiki, Hiroki Morita, Atsushi Ogawa, Mitsuhiro Yanai, Tetsuro Ohno, Takaaki Fujii, Soichi Tsutsumi, Takayuki Asao, Hiroyuki Kuwano.   

Abstract

BACKGROUND AND AIMS: Postoperative ileus is a transient bowel dysmotility that occurs following many types of operations and is a common complication of gastrointestinal surgery. Mosapride citrate is an agonist of the 5-hydroxytryptamine 4 receptor and accelerates upper gut motility. No study has evaluated its effect on gastrointestinal motility after surgery. The aim of this study was to investigate whether mosapride citrate reduces the duration of postoperative ileus.
METHODS: Thirty patients with colon cancer who underwent colectomy were divided into two groups: the mosapride group and the control group. The mosapride group received mosapride 15 mg by mouth with a minimal amount of water three times a day, starting on postoperative day 1. The control group received only a minimal amount of water on the same schedule. Patients were allowed to resume oral feeding on postoperative day 4. Postoperative time to first flatus and defecation were evaluated, and the amount of food intake was observed. Gastrointestinal motility was recorded on postoperative day 8.
RESULTS: The appearance ratio of interdigestive migrating contractions and the motility index at the antrum and duodenum were significantly higher in the mosapride group than in the control group. The time to first flatus and defecation were significantly shorter in the mosapride group than in the control group. The amount of food intake on postoperative days 6 and 7 was significantly larger in the mosapride group than in the control group.
CONCLUSION: Mosapride citrate reduces the duration of postoperative ileus and may improve outcomes after gastrointestinal surgery.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21607794     DOI: 10.1007/s11605-011-1567-x

Source DB:  PubMed          Journal:  J Gastrointest Surg        ISSN: 1091-255X            Impact factor:   3.452


  15 in total

1.  5-HT4 receptor enhances the propulsive power of the peristaltic reflex in the rat distal colon.

Authors:  Makoto Kadowaki; Xia Obiao Wang; Hidehiko Shimatani; Satoshi Yoneda; Miyako Takaki
Journal:  Auton Neurosci       Date:  2002-07-31       Impact factor: 3.145

2.  AS-4370, a new gastrokinetic agent, enhances upper gastrointestinal motor activity in conscious dogs.

Authors:  N Yoshida; T Ito; T Karasawa; Z Itoh
Journal:  J Pharmacol Exp Ther       Date:  1991-05       Impact factor: 4.030

3.  Ability of mosapride to bind to 5-HT4 receptor in the human stomach.

Authors:  Y Sakurai-Yamashita; K Takada; K Takemura; K Yamashita; A Enjoji; T Kanematsu; K Taniyama
Journal:  Jpn J Pharmacol       Date:  1999-04

4.  Comparison of effect of mosapride citrate and existing 5-HT4 receptor agonists on gastrointestinal motility in vivo and in vitro.

Authors:  Y Mine; T Yoshikawa; S Oku; R Nagai; N Yoshida; K Hosoki
Journal:  J Pharmacol Exp Ther       Date:  1997-12       Impact factor: 4.030

5.  Impaired gastric motility and its relationship to reflux symptoms in patients with nonerosive gastroesophageal reflux disease.

Authors:  Takeshi Kamiya; Hiroshi Adachi; Makoto Hirako; Michiko Shikano; Eriko Matsuhisa; Tsuneya Wada; Naotaka Ogasawara; Shunsuke Nojiri; Hiromi Kataoka; Makoto Sasaki; Hirotaka Ohara; Takashi Joh
Journal:  J Gastroenterol       Date:  2009-02-13       Impact factor: 7.527

6.  A 5-HT4 agonist mosapride enhances rectorectal and rectoanal reflexes in guinea pigs.

Authors:  Hidehiko Shimatani; Yu Kojima; Makoto Kadowaki; Tadashi Nakagawa; Hisao Fujii; Yoshiyuki Nakajima; Miyako Takaki
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2003-04-30       Impact factor: 4.052

7.  Postoperative functional evaluation of jejunal interposition with or without a pouch after a total gastrectomy for gastric cancer.

Authors:  Erito Mochiki; Yoichi Kamiyama; Ryusuke Aihara; Toshihiro Nakabayashi; Hitoshi Kamimura; Takayuki Asao; Hiroyuki Kuwano
Journal:  Am J Surg       Date:  2004-06       Impact factor: 2.565

8.  5-Amino-6-chloro-N-[(1-isobutylpiperidin-4-yl)methyl]-2-methylimidazo[1,2-alpha]pyridine-8-carboxamide (CJ-033,466), a novel and selective 5-hydroxytryptamine4 receptor partial agonist: pharmacological profile in vitro and gastroprokinetic effect in conscious dogs.

Authors:  Tadayoshi Mikami; Yasuo Ochi; Keiko Suzuki; Toshiyuki Saito; Yutaka Sugie; Minoru Sakakibara
Journal:  J Pharmacol Exp Ther       Date:  2008-01-15       Impact factor: 4.030

9.  Oral mitemcinal (GM-611), an erythromycin-derived prokinetic, accelerates normal and experimentally delayed gastric emptying in conscious dogs.

Authors:  Mitsu Onoma; Kenji Yogo; Ken-Ichi Ozaki; Kenshi Kamei; Michitaka Akima; Hiroshi Koga; Zen Itoh; Satoshi Omura; Hisanori Takanashi
Journal:  Clin Exp Pharmacol Physiol       Date:  2008-01       Impact factor: 2.557

10.  Effects of mosapride citrate, a 5-HT4 receptor agonist, on colonic motility in conscious guinea pigs.

Authors:  Atsuko Inui; Takashi Yoshikawa; Ryuji Nagai; Naoyuki Yoshida; Tsugutaka Ito
Journal:  Jpn J Pharmacol       Date:  2002-12
View more
  9 in total

Review 1.  Defining postoperative ileus: results of a systematic review and global survey.

Authors:  Ryash Vather; Sid Trivedi; Ian Bissett
Journal:  J Gastrointest Surg       Date:  2013-02-02       Impact factor: 3.452

Review 2.  New therapeutic strategies for postoperative ileus.

Authors:  Sjoerd H W van Bree; Andrea Nemethova; Cathy Cailotto; Pedro J Gomez-Pinilla; Gianluca Matteoli; Guy E Boeckxstaens
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2012-07-17       Impact factor: 46.802

Review 3.  Pharmacological management to prevent ileus in major abdominal surgery: a systematic review and meta-analysis.

Authors:  T M Drake; A E Ward
Journal:  J Gastrointest Surg       Date:  2016-04-12       Impact factor: 3.452

4.  Risk factors for postoperative ileus following orthopedic surgery: the role of chronic constipation.

Authors:  Tae Hee Lee; Joon Seong Lee; Su Jin Hong; Jae Young Jang; Seong Ran Jeon; Dong Won Byun; Won Young Park; Soon Im Kim; Hyung Suk Choi; Jae Chul Lee; Ji Sung Lee
Journal:  J Neurogastroenterol Motil       Date:  2015-01-01       Impact factor: 4.924

5.  SmartPill® as an objective parameter for determination of severity and duration of postoperative ileus: study protocol of a prospective, two-arm, open-label trial (the PIDuSA study).

Authors:  Tim O Vilz; Dimitrios Pantelis; Philipp Lingohr; Rolf Fimmers; Anke Esmann; Thomas Randau; Jörg C Kalff; Martin Coenen; Sven Wehner
Journal:  BMJ Open       Date:  2016-07-08       Impact factor: 2.692

6.  Ameliorating Effects of Electroacupuncture on Dysmotility, Inflammation, and Pain Mediated via the Autonomic Mechanism in a Rat Model of Postoperative Ileus.

Authors:  Haruaki Murakami; Shiying Li; Robert Foreman; Jieyun Yin; Toshihiro Hirai; Jiande D Z Chen
Journal:  J Neurogastroenterol Motil       Date:  2019-04-30       Impact factor: 4.924

7.  Association between Blood Potassium Level and Recovery of Postoperative Gastrointestinal Motility during Continuous Renal Replacement Therapy in Patient Undergoing Open Abdominal Surgery.

Authors:  Yi Yang; Jingjuan Yang; Xiner Yao; Yu Cui; Xiabing Lang; Binbin Wu; Ping Zhang; Jianghua Chen
Journal:  Biomed Res Int       Date:  2019-07-02       Impact factor: 3.411

8.  Enhanced Recovery after Surgery Protocol Accelerates Recovery of Lumbar Disc Herniation among Elderly Patients Undergoing Discectomy via Promoting Gastrointestinal Function.

Authors:  Xiaohai Zuo; Linbang Wang; Longzhu He; Pei Li; Dandan Zhou; Yiping Yang
Journal:  Pain Res Manag       Date:  2021-11-22       Impact factor: 3.037

9.  Purinergic P2X7 receptor antagonist ameliorates intestinal inflammation in postoperative ileus.

Authors:  Hitomi Kimura; Takako Yamazaki; Taiki Mihara; Noriyuki Kaji; Kazuhisa Kishi; Masatoshi Hori
Journal:  J Vet Med Sci       Date:  2022-03-07       Impact factor: 1.267

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.